AcelRx Pharmaceuticals appoints Gina Ford as Vice President Commercial Strategy

She was been a consultant to the company since 2013

AcelRx Pharmaceuticals, a developer of innovative therapies for the treatment of acute pain, has appointed Gina Ford as Vice President of Commercial Strategy.

Ford has been working with AcelRx as a consultant since 2013 and has been instrumental in the development of a commercial strategy for Zalviso (sufentanil sublingual tablet system), a drug-device combination product now approved in Europe for the management of acute moderate-to-severe post-operative pain in adult patients. In her new role Ford will be responsible for developing the commercial plan for ARX-04 in the US, Europe and other regions.

Before joining the AcelRx management team, Ford was sole proprietor of One Joule, a commercial strategy consulting company. Before this she was President of Accesia, a wholly owned subsidiary of Patient Services, and held several leadership roles at Ipsen, a global pharmaceutical company focusing on neurology, endocrinology and urology-oncology.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now